Gene therapy and liver disease;Thérapie génique des maladies du foie

Gastroenterologie Clinique et Biologique

Volumn 27, Issue 3 I, 2003, Pages 288-290

  Ferry, Nicolas ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; LENTIVIRUS VECTOR; PROTEIN P53; RETROVIRUS VECTOR; THYMIDINE KINASE;

DRUG INDICATION; GENE TARGETING; GENE THERAPY; HUMAN; LIVER DISEASE; SHORT SURVEY;

GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC DISEASES, INBORN; GENETIC VECTORS; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 0037363985     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (14)

1. Ferry N, Heard JM. Liver-directed gene transfer vectors. Hum Gene Ther 1998;9:1975-81.
2. Grossman M, Rader DJ, Muler DWM, Kolansky DM, Kozarsky K, Clark III BJ, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolemia. Nat Med 1995;1:1148-54.
3. Raper SE, Yudkoff M, Chirmule N, Gao GP, Nunes F, Haskal ZJ, et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther 2002;13:163-75.
4. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000;24:257-61.
5. Ponder KP, Melniczek JR, Xu L, Weil MA, O'Malley TM, O'Donnell PA, et al. Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs. Proc Natl Acad Sci U S A 2002;99:13102-7.
6. Brown BD, Lillicrap D. Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy. Blood 2002;100:1133-40.
7. Arbuthnot PB, Bralet MP, LeJossic C, Dedieu JF, Perricaudet M, Bréchot C, et al. In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector. Hum Gene Ther 1996;7:1503-14.
8. Gerolami R, Cardoso J, Lewin M, Bralet MP, Sa Cunha A, Clement O, et al. Evaluation of HSV-tk gene therapy in a rat model of chemically induced hepatocellular carcinoma by intratumoral and intrahepatic artery routes. Cancer Res 2000;60:993-1001.
9. Habib NA, Hodgson HJ, Lemoine N, Pignatelli M. A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours. Hum Gene Ther 1999;10:2019-34.
10. Habib NA, Ding SF, el-Masry R, Mitry RR, Honda K, Michail NE, et al. Preliminary report: the short-term effects of direct p53 DNA injection in primary hepatocellular carcinomas. Cancer Detect Prev 1996;20:103-7.
11. Moolten F. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986;46:5276-81.
12. Melero I, Mazzolini G, Narvaiza I, Qian C, Chen L, Prieto J. IL-12 gene therapy for cancer: in synergy with other immunotherapies. Trends Immunol 2001;22:113-5.
13. Meng WS, Butterfield LH, Ribas A, Dissette VB, Heller JB, Miranda GA, et al. alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res 2001;61:8782-6.
14. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000;288:669-72.